Cambridge Investment Research Advisors, Inc. Vir Biotechnology, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 17, 2022	BUY	$18.26 - $31.1 $208,638 - $355,348	11,426 New	11,426 $220,000
Q1 2022 May 12, 2022	SELL	$21.19 - $40.01 $216,667 - $409,102	-10,225 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$30.97 - $54.03 $141,378 - $246,646	-4,565 Reduced 30.87%	10,225 $428,000
Q3 2021 Nov 02, 2021	BUY	$34.9 - $54.54 $149,023 - $232,885	4,270 Added 40.59%	14,790 $643,000
Q2 2021 Aug 10, 2021	BUY	$38.75 - $51.0 $5,812 - $7,650	150 Added 1.45%	10,520 $497,000
Q1 2021 May 07, 2021	BUY	$26.34 - $83.07 $273,145 - $861,435	10,370 New	10,370 $531,000

Others Institutions Holding VIR

# of Institutions

218

Shares Held

87M

Call Options Held

127K

Put Options Held

1.19M

Sb Investment Advisers (Uk) LTD London, X0

16.7M
Shares

$123 Million
1.03% of portfolio
Black Rock Inc. New York, NY

16.4M
Shares

$122 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$97.2 Million
0.0% of portfolio
State Street Corp Boston, MA

5.63M
Shares

$41.6 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

3.57M
Shares

$26.4 Million
0.63% of portfolio

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account